PPARGC1A and Parkinson disease: Mitochondria-targeted biomimetic nanoparticles can promote neuronal mitochondrial biogenesis by regulating the NAD/SIRT1/PGC-1α/PPARγ/NRF1/TFAM pathway, thereby ameliorating mitochondrial dysfunction and alleviating PD symptoms (44).